Why Infinity Pharmaceuticals Inc. Shares Jumped
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Infinity Pharmaceuticals , a clinical-stage biopharmaceutical company developing therapies to treat unmet medical needs, advanced as much as 22% after reporting its third-quarter results and providing a pipeline update.
So what: For the quarter, Infinity did not record any revenue -- not a surprise given that it's in the clinical-stages of drug development -- and reported a net loss of $33.9 million, or an adjusted $0.71 per share loss, compared to a profit of $0.52 per share in the previous year. Despite the reversal of fortune amid higher R&D expenses, the loss of $0.71 met the Street's expectations.
What's really invigorating investors today is the company's update of blood cancer drug IPI-145 which is turning a lot of heads with its potential early on in the development process. According to the company's press release, Infinity will be presenting five abstracts of preclinical and clinical data involving IPI-145 at the American Society of Hematology meeting next month. In addition, Infinity plans to offer "preclinical and/or translational data," as it put it, for IPI-145 as a treatment for a number of other cancer-based malignancies.
Now what: There's obviously a lot of excitement surrounding IPI-145 with the drug demonstrating early stage and preclinical anti-cancer activity, but I'd like to remind investors that Infinity is still, in all likelihood, years away from bringing a drug to market. The share price rallied in a big way earlier this year on IPI-145's promise only to lose all of those gains and some when investors, too, came to realize this point. While I'm not saying Infinity is a company I'd suggest staying away from here as the promise for a blockbuster is certainly there, I'd absolutely suggest keeping your expectations in check until we get broader study data on IPI-145 in phase 2 and 3 trials.
Are you missing out on this humongous growth opportunity?
Infinity's IPI-145 isn't the only thing around here with amazing potential. You should also check out this incredible tech stock which is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this company will be a huge winner in 2013 and beyond. Just click here to watch!
The article Why Infinity Pharmaceuticals Inc. Shares Jumped originally appeared on Fool.com.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.